See more : Menara Ventures Xl – Limited Partnership (MNRA.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Zomedica Corp. (ZOM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zomedica Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Energoinstal S.A. (ENI.WA) Income Statement Analysis – Financial Results
- InhaleRx Limited (IRX.AX) Income Statement Analysis – Financial Results
- Entrust Inc. (7191.T) Income Statement Analysis – Financial Results
- Dalian Friendship (Group) Co., Ltd. (000679.SZ) Income Statement Analysis – Financial Results
- Fuji Kosan Company, Ltd. (5009.T) Income Statement Analysis – Financial Results
Zomedica Corp. (ZOM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zomedica.com
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.19M | 18.93M | 4.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.87M | 5.28M | 1.08M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.32M | 13.65M | 3.05M | -530.02K | -787.61K | -205.77K | -92.41K | -45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 68.76% | 72.12% | 73.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.74M | 2.58M | 1.67M | 8.04M | 10.35M | 10.32M | 2.75M | 1.52M | 758.05K | 0.00 | 0.00 |
| General & Administrative | 29.03M | 22.93M | 0.00 | 7.93M | 8.18M | 5.83M | 5.08M | 4.24M | 1.43M | 42.41K | 77.50K |
| Selling & Marketing | 14.14M | 9.88M | 0.00 | 261.91K | 471.89K | 225.89K | 164.25K | 194.19K | 143.47K | 0.00 | 0.00 |
| SG&A | 43.17M | 33.00M | 22.75M | 8.19M | 8.65M | 6.06M | 5.24M | 4.43M | 1.57M | 42.41K | 77.50K |
| Other Expenses | 0.00 | -7.00K | 6.00K | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.91M | 35.58M | 24.43M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Cost & Expenses | 56.78M | 40.85M | 25.51M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Interest Income | 5.46M | 2.70M | 357.45K | 32.86K | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 175.00K | 1.00K | 6.05K | 732.00 | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.30M | 4.04M | 1.14M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 9.05K | 0.00 | 0.00 |
| EBITDA | -29.39M | -15.34M | -19.57M | -16.38M | -19.00M | -16.44M | -7.97M | -5.97M | -2.28M | -42.41K | -77.50K |
| EBITDA Ratio | -116.68% | -80.23% | -479.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.59M | -21.92M | -21.37M | -16.76M | -19.78M | -16.58M | -8.08M | -6.00M | -2.29M | -42.41K | -77.50K |
| Operating Income Ratio | -125.43% | -115.81% | -517.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.27M | 2.54M | 657.78K | -146.81K | 273.00 | -68.44K | 18.98K | 258.06K | 7.44K | 0.00 | 0.00 |
| Income Before Tax | -35.86M | -19.38M | -20.72M | -16.91M | -19.78M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Income Before Tax Ratio | -142.38% | -102.38% | -501.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.33M | -2.37M | -2.33M | 9.33K | 38.08K | 136.88K | -18.98K | 28.59K | 0.00 | 0.00 | 0.00 |
| Net Income | -34.53M | -17.02M | -18.38M | -16.92M | -19.82M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Net Income Ratio | -137.10% | -89.88% | -444.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| EPS Diluted | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| Weighted Avg Shares Out | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 92.49M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
| Weighted Avg Shares Out (Dil) | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 93.44M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the commercial launch of three...
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
ANN ARBOR, MI / ACCESSWIRE / December 6, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of new clinical...
Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
ANN ARBOR, MI / ACCESSWIRE / November 28, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will be attending...
Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
ANN ARBOR, MI / ACCESSWIRE / November 20, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will attend the...
Zomedica Corp. (ZOM) Q3 2023 Earnings Call Transcript
Zomedica Corp. (NYSE:ZOM ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Elif McDonald - Investor Relations Larry Heaton - Chief Executive Officer Peter Donato - Chief Financial Officer Conference Call Participants Jason Kolbert -...
Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies
ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the quarter ended...
Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / November 2, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on...
Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
ANN ARBOR, MI / ACCESSWIRE / October 11, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Larry Heaton, Chief Executive Officer, will present...
Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic devices for companion animals, today announced the acquisition of Qorvo Biotechnologies LLC (QBT), creators...
Zomedica, Inc. to Present at the LD Micro Main Event XVI
Presentation on Tuesday, October 3rd at 1:00 PM PT Ann Arbor, Michigan--(Newsfile Corp. - September 27, 2023) - Zomedica Corp. (NYSE American: ZOM) (the "Company") announced today that the Company is scheduled to provide a strategic overview and its prospects...
Source: https://incomestatements.info
Category: Stock Reports
How has Zomedica’s diagnostic product revenue grown?
Zomedica (NYSE:ZOM) reported Q3 2024 financial results with revenue growing 10% to $7.0 million, maintaining a strong gross margin of 72.3%. The Diagnostics segment grew 38%, while the Therapeutic Device segment increased 9%.
What were Zomedica’s revenue and losses in the last 12 months?
In the last 12 months, Zomedica had revenue of $26.73 million and -$62.19 million in losses. Loss per share was -$0.06.